Today: 19 April 2026
Why IonQ, D-Wave and Rigetti Stocks Are Falling After Mizuho Cut Price Targets
8 April 2026
2 mins read

Why IonQ, D-Wave and Rigetti Stocks Are Falling After Mizuho Cut Price Targets

UPDATE: New York, April 8, 2026, 11:20 (EDT).

As of the latest quoted trades around 11:01 a.m. EDT, IonQ was at $28.83, D-Wave at $14.17, and Rigetti at $14.25, leaving all three above their previous closes but below the session’s highs.

On April 7, Rigetti announced general availability of its 108-qubit Cepheus-1-108Q system through QCS and Amazon Braket, with current median two-qubit gate fidelity of 99.1% and a 99.5% target later this year.

On March 16, IonQ said it had formed a South Korea alliance with KISTI to integrate its quantum hardware with HPC infrastructure using NVIDIA NVQLink.

In January, D-Wave said Advantage2 usage had climbed 314% over the prior year and that it planned to bring an initial gate-model quantum computing system to market in 2026.

New York, April 8, 2026, 07:02 EDT

Shares of IonQ, D-Wave Quantum, and Rigetti Computing dropped on Wednesday, following a round of price target cuts from Mizuho’s Vijay Rakesh. The analyst took his targets down to $61 for IonQ, $31 for D-Wave, and $33 for Rigetti—previously set at $80, $40, and $43—while sticking with Outperform ratings. The trio already shed about 4% on Tuesday.

Mizuho’s latest cuts come after a fresh look at the sector, prompted by Nvidia’s GTC conference and a string of recent industry updates. Wall Street isn’t backing out; it’s just dialing down short-term hopes. The broker pointed to the increasing adoption of NVQLink — tech that connects quantum processors with conventional accelerated computing — as a possible boost for quantum error correction, which tackles errors in unstable qubits. Competition to surpass 200 logical qubits, meaning error-corrected qubits reliable enough for practical tasks, is picking up speed for the 2027-2029 window.

D-Wave’s fresh disclosures shed some light on why the broker held onto its bullish view. On Feb. 26, the company reported it wrapped up 2025 with $884.5 million in cash and marketable securities, after pulling in over $800 million over the year. Even after spending $250 million on the Quantum Circuits buyout, D-Wave said its remaining liquidity should carry it through to profitability.

D-Wave reported that its 2026 bookings so far have already topped any previous full-year result, with the sales pipeline for 2026 almost 1,500% higher. Kicking off the year, D-Wave landed a $20 million system sale with Florida Atlantic University and also secured a $10 million, two-year QCaaS deal—cloud-based quantum computing access—with a Fortune 100 firm. According to CFO John Markovich, operating expenses are projected to climb roughly 15% each quarter through 2026. CEO Alan Baratz described 2026 as “a defining year for D-Wave.” D-Wave

IonQ posted $130 million in 2025 revenue and sat on $3.3 billion in cash, cash equivalents, and investments. Looking ahead, the company guided for 2026 revenue of $225 million to $245 million. “Continued momentum” toward that 2026 goal, CEO Niccolo de Masi said. IonQ Investors

Rigetti isn’t pulling in big revenue, but the balance sheet looks sturdy. The company reported $1.9 million in fourth-quarter revenue and held $44.9 million in cash as of March 4, with $398.7 million in short-term investments and $146.3 million in long-term holdings. About three weeks out from those numbers, Rigetti announced plans to put as much as $100 million into the UK, where the government’s quantum roadmap includes up to £2 billion in funding. Chief Executive Subodh Kulkarni pointed to what he called “strong alignment” between Rigetti and the UK’s strategy. Rigetti Co, LLC

But risks in the short run are clear enough. D-Wave warned investors its system sales might not show up as revenue for months or even quarters, given the lengthy installation timeline. Rigetti’s sales numbers are still on the small side. Over at IonQ, the company is forecasting an adjusted EBITDA loss between $310 million and $330 million for 2026, despite revenue growth.

Mizuho isn’t backing down from its optimism, maintaining bullish ratings and pointing to more than 100% upside across the sector. Investors, though, face the usual picture: quantum companies flush with cash and lofty plans, while real commercial momentum remains elusive.

Stock Market Today

  • Parasite Pool Mines Second Bitcoin Block with Unique Hybrid Mining Model
    April 19, 2026, 12:47 AM EDT. Parasite Pool, a bitcoin mining pool launched in April 2025, has mined its second block, demonstrating its hybrid mining model. Unlike traditional pools, Parasite awards the winning miner 1 BTC outright, distributing the remaining 2.125 BTC plus transaction fees proportionally among participants. The model blends solo and pool mining benefits, offering steady payouts without participation fees. Bitcoin's current block reward stands at 3.125 BTC, down from 6.25 BTC after the 2024 halving. Parasite's current hashrate is 52 PH/s, about 0.005% of the total bitcoin network. The pool retains steady hashrate amid industry dominance by large-scale industrial miners. This second block confirms Parasite's model works in practice, sustaining user engagement between blocks and providing a new approach for home miners competing in a high-stakes market.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 19.04.2026

19 April 2026
LIVEMarkets rolling coverageStarted: April 19, 2026, 12:00 AM EDTUpdated: April 19, 2026, 12:48 AM EDT GSK Shares Surge to Highest Since 2000 on Strong Results and Investor Interest April 19, 2026, 12:48 AM EDT. GSK's shares hit 2,125p on April 17, their highest since November 2000, driven by strong full-year results and renewed investor demand. Sales rose 7% to £32.7 billion and operating profit increased 11% to £9.8 billion, beating expectations. New CEO Luke Miels upheld growth targets aiming for £40 billion sales by 2031. Despite a recent dividend cut, GSK has increased payouts recently, supported by a 41% jump
Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Gas Prices Stay High After Iran Ceasefire as Mono County Drivers Face the Nation’s Steepest Prices
Previous Story

Gas Prices Stay High After Iran Ceasefire as Mono County Drivers Face the Nation’s Steepest Prices

Occidental Petroleum Stock Slides With Oil as Wolfe Research Lifts OXY Target and Hollub Exit Talk Builds
Next Story

Occidental Petroleum Stock Slides With Oil as Wolfe Research Lifts OXY Target and Hollub Exit Talk Builds

Go toTop